Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,582 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all

Conditions: Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Interventions: Glucagon, Placebo; Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Birmingham, Alabama • San Diego, California • Atlanta, Georgia + 1 more

Conditions: Type 1 Diabetes
Interventions: Vitamin D, Placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 4 Years to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes, Type 1
Interventions: Observation; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 1 Diabetes Mellitus
Interventions: Pet Fish, Picture of a fish; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 10 Years to 17 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 1 Diabetes
Interventions: Bionic Pancreas, Usual Care; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 11 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Teplizumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 8 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Newly Diagnosed With Type 1 Diabetes
Interventions: Zenapax; Drug
Lead sponsor: Indiana University; Other
Eligibility: 2 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 1 Diabetes
Interventions: Type 1 Doing Well (T1DW) Program, Diabetes-Related Information and Resources Program; Behavioral · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 99 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes, Type 1 Diabetes, Pregnancy, High Risk
Interventions: Mid-Ohio Food Farmacy (MOF+) produce delivery, Nutrition education with Dining with Diabetes (DWD), Health Impact Ohio Central Ohio Pathways Hub to address unmet social needs; Dietary Supplement · Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes
Interventions: Diabetes-suppressive dendritic cell vaccine, control dendritic cells; Biological
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Cytal Wound Matrix 1-Layer, Standard of Care (SOC); Device · Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland

Conditions: Diabetes Mellitus, Type 1
Interventions: t:slim X2 pump with Control-IQ technology; Device
Lead sponsor: Tandem Diabetes Care, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 3,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Type 1 Diabetes Mellitus
Interventions: CARES Intervention; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 5 Years to 12 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Stress, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Mindfulness Based Stress Reduction, Stress Management Education; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Type1diabetes, Type1 Diabetes Mellitus
Interventions: VSL#3; Dietary Supplement
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Type 1 Diabetes Mellitus
Interventions: HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Temecula, California • Minneapolis, Minnesota • Portland, Oregon

Conditions: Type 1 Diabetes
Interventions: Sugar Sleuth; Behavioral
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 25 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Bolus timing and dosing; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 7 Years to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes, Celiac Disease
Interventions: Combined Risk Score; Diagnostic Test
Lead sponsor: Pacific Northwest Research Institute; Other
Eligibility: 1 Day to 7 Years
Enrollment: 64,410 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: IDDM
Interventions: Continuous Pramlintide infusion; Drug
Lead sponsor: University Diabetes & Endocrine Consultants; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Type 1 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions: GlucoSTAT; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes (T1D)
Interventions: Golimumab, Placebo (matching golimumab); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 44 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Fatty Liver, Obesity, Healthy Volunteers
Interventions: Alpha tocopherol, Vitamin E, Vitamin C; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 1, Hypoglycemia Unawareness
Interventions: Dichloroacetate; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes

Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant

Pet Ownership and Glucose Control in Type 1 Diabetes

The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas

A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States

Prevention of Diabetes Progression Trial (PDPT)

EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes

NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes

Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

Control-IQ Observational (CLIO) Post-Approval Study

Cognitive Adaptations to Reduce Emotional Stress Associated With Type 1 Diabetes

Decreasing Stress in Diabetes

Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

Use of Mobile-based Technologies to Improve Diabetes Self-management and Postprandial Glucose Control

Timing of Pre-meal Insulin Versus Accurate Carbohydrate Counting in Youth With Type 1 Diabetes

Combined Antibody Screening for Celiac and Diabetes Evaluation

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

Regulation of Brain Glucose Metabolism in Type 1 Diabetes